Sex differences in kidney gene expression during the life cycle of F344 rats

Biology of Sex Differences

Joshua C Kwekel¹  Varsha G Desai¹  Carrie L Moland¹  Vikrant Vijay¹  James C Fuscoe¹ 

[1] Personalized Medicine Branch, Division of Systems Biology, National Center for Toxicological Research, US Food and Drug Administration, 3900 NCTR Road, Jefferson, AR 72079, USA

关键词: Biomarker;    Age;    Sex;    Gene expression;    Kidney;   

Others  :  793044
DOI  :  10.1186/2042-6410-4-14

 received in 2013-01-25, accepted in 2013-07-06,  发布年份 2013

【 摘 要 】

Background

The kidney functions in key physiological processes to filter blood and regulate blood pressure via key molecular transporters and ion channels. Sex-specific differences have been observed in renal disease incidence and progression, as well as acute kidney injury in response to certain drugs. Although advances have been made in characterizing the molecular components involved in various kidney functions, the molecular mechanisms responsible for sex differences are not well understood. We hypothesized that the basal expression levels of genes involved in various kidney functions throughout the life cycle will influence sex-specific susceptibilities to adverse renal events.

Methods

Whole genome microarray gene expression analysis was performed on kidney samples collected from untreated male and female Fischer 344 (F344) rats at eight age groups between 2 and 104 weeks of age.

Results

A combined filtering approach using statistical (ANOVA or pairwise t test, FDR 0.05) and fold-change criteria (>1.5 relative fold change) was used to identify 7,447 unique differentially expressed genes (DEGs). Principal component analysis (PCA) of the 7,447 DEGs revealed sex-related differences in mRNA expression at early (2 weeks), middle (8, 15, and 21 weeks), and late (104 weeks) ages in the rat life cycle. Functional analysis (Ingenuity Pathway Analysis) of these sex-different genes indicated over-representation of specific pathways and networks including renal tubule injury, drug metabolism, and immune cell and inflammatory responses. The mRNAs that code for the qualified urinary protein kidney biomarkers KIM-1, Clu, Tff3, and Lcn2 were also observed to show sex differences.

Conclusions

These data represent one of the most comprehensive in-life time course studies to be published, assessing sex differences in global gene expression in the F344 rat kidney. PCA and Venn analyses reveal specific periods of sexually dimorphic gene expression which are associated with functional categories (xenobiotic metabolism and immune cell and inflammatory responses) of key relevance to acute kidney injury and chronic kidney disease, which may underlie sex-specific susceptibility. Analysis of the basal gene expression patterns of renal genes throughout the life cycle of the rat will improve the use of current and future renal biomarkers and inform our assessments of kidney injury and disease.

【 授权许可】

   
2013 Kwekel et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Trevisan A, Chiara F, Mongillo M, Quintieri L, Cristofori P: Sex-related differences in renal toxicodynamics in rodents. Expert Opin Drug Metab Toxicol 2012, 8(9):1173-1188.
• [2]Sabolic I, Asif AR, Budach WE, Wanke C, Bahn A, Burckhardt G: Gender differences in kidney function. Pflugers Arch 2007, 455(3):397-429.
• [3]McGuire BB, Watson RW, Perez-Barriocanal F, Fitzpatrick JM, Docherty NG: Gender differences in the renin-angiotensin and nitric oxide systems: relevance in the normal and diseased kidney. Kidney Blood Press Res 2007, 30(2):67-80.
• [4]Kang AK, Miller JA: Impact of gender on renal disease: the role of the renin angiotensin system. Clin Invest Med 2003, 26(1):38-44.
• [5]Kang DH, Yu ES, Yoon KI, Johnson R: The impact of gender on progression of renal disease: potential role of estrogen-mediated vascular endothelial growth factor regulation and vascular protection. Am J Pathol 2004, 164(2):679-688.
• [6]Silbiger S, Neugarten J: Gender and human chronic renal disease. Gend Med 2008, 5:S3-S10.
• [7]Silbiger SR, Neugarten J: The role of gender in the progression of renal disease. Adv Ren Replace Ther 2003, 10(1):3-14.
• [8]Seliger SL, Davis C, Stehman-Breen C: Gender and the progression of renal disease. Curr Opin Nephrol Hypertens 2001, 10(2):219-225.
• [9]Yu MK, Lyles CR, Bent-Shaw LA, Young BA: Risk factor, age and sex differences in chronic kidney disease prevalence in a diabetic cohort: the pathways study. Am J Nephrol 2012, 36(3):245-251.
• [10]Sweileh WM: Gender differences in aminoglycoside induced nephrotoxicity: a prospective, hospital-based study. Curr Clin Pharmacol 2009, 4(3):229-232.
• [11]Omara EA, Aly HF, Nada SA: Chitosan induced hepato-nephrotoxicity in mice with special reference to gender effect in glycolytic enzymes activities. Regul Toxicol Pharmacol 2012, 62(1):29-40.
• [12]Al-Rejaie SS, Abuohashish HM, Alkhamees OA, Aleisa AM, Alroujayee AS: Gender difference following high cholesterol diet induced renal injury and the protective role of rutin and ascorbic acid combination in Wistar albino rats. Lipids Health Dis 2012, 11:41. BioMed Central Full Text
• [13]Hazelhoff MH, Bulacio RP, Torres AM: Gender related differences in kidney injury induced by mercury. Int J Mol Sci 2012, 13(8):10523-10536.
• [14]Bloor ID, Sebert SP, Mahajan RP, Symonds ME: The influence of sex on early stage markers of kidney dysfunction in response to juvenile obesity. Hypertension 2012, 60(4):991-997.
• [15]Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004, 3(8):711-715.
• [16]Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV: Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002, 62(1):237-244.
• [17]Ozer JS, Dieterle F, Troth S, Perentes E, Cordier A, Verdes P, Staedtler F, Mahl A, Grenet O, Roth DR, Wahl D, Legay F, Holder D, Erdos Z, Vlasakova K, Jin H, Yu Y, Muniappa N, Forest T, Clouse HK, Reynolds S, Bailey WJ, Thudium DT, Topper MJ, Skopek TR, Sina JF, Glaab WE, Vonderscher J, Maurer G, Chibout SD, et al.: A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat Biotechnol 2010, 28(5):486-494.
• [18]Mendrick DL: Transcriptional profiling to identify biomarkers of disease and drug response. Pharmacogenomics 2011, 12(2):235-249.
• [19]Kwekel JC, Desai VG, Moland CL, Branham WS, Fuscoe JC: Age and sex dependent changes in liver gene expression during the life cycle of the rat. BMC Genomics 2010, 11:675. BioMed Central Full Text
• [20]Fang H, Harris SC, Su Z, Chen M, Qian F, Shi L, Perkins R, Tong W: ArrayTrack: an FDA and public genomic tool. Methods Mol Biol 2009, 563:379-398.
• [21]Dieterle F, Perentes E, Cordier A, Roth DR, Verdes P, Grenet O, Pantano S, Moulin P, Wahl D, Mahl A, End P, Staedtler F, Legay F, Carl K, Laurie D, Chibout SD, Vonderscher J, Maurer G: Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat Biotechnol 2010, 28(5):463-469.
• [22]Quinn R: Comparing rat’s to human’s age: how old is my rat in people years? Nutrition 2005, 21(6):775-777.
• [23]Madeddu P, Vio CP, Straino S, Salis MB, Milia AF, Emanueli C: Renal phenotype of low kallikrein rats. Kidney Int 2001, 59(6):2233-2242.
• [24]Miyazawa M, Shindo M, Shimada T: Sex differences in the metabolism of (+)- and (−)-limonene enantiomers to carveol and perillyl alcohol derivatives by cytochrome p450 enzymes in rat liver microsomes. Chem Res Toxicol 2002, 15(1):15-20.
• [25]National Toxicology Program: NTP toxicology and carcinogenesis studies of d-limonene (CAS No. 5989-27-5) in F344/N rats and B6C3F1 mice (gavage studies). Natl Toxicol Program Tech Rep Ser 1990, 347:1-165.
• [26]Pfeiffer E, Metzler M: Effect of bisphenol A on drug metabolising enzymes in rat hepatic microsomes and precision-cut rat liver slices. Arch Toxicol 2004, 78(7):369-377.
• [27]Klaassen CD, Aleksunes LM: Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 2010, 62(1):1-96.
• [28]Kasenda B, Rehberg M, Thurmann P, Franzem M, Veelken H, Fritsch K, Schorb E, Finke J, Lebiedz D, Illerhaus G: The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients. Ann Hematol 2012, 91(8):1257-1264.
• [29]Iwano S, Higashi E, Miyoshi T, Ando A, Miyamoto Y: Focused DNA microarray analysis for sex-dependent gene expression of drug metabolizing enzymes, transporters and nuclear receptors in rat livers and kidneys. J Toxicol Sci 2012, 37(4):863-869.
• [30]Waxman DJ, Holloway MG: Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol 2009, 76(2):215-228.
• [31]Espandiari P, Rosenzweig B, Zhang J, Zhou Y, Schnackenberg L, Vaidya VS, Goering PL, Brown RP, Bonventre JV, Mahjoob K, Holland RD, Beger RD, Thompson K, Hanig J, Sadrieh N: Age-related differences in susceptibility to cisplatin-induced renal toxicity. J Appl Toxicol 2010, 30(2):172-182.